|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Pediatric and Adolescent Osteosarcoma. Jaffe N,
Bruland OS and Bielack S: Springer US; pp. 3–13. 2010
|
|
2
|
Botter SM, Neri D and Fuchs B: Recent
advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Linabery AM and Ross JA: Trends in
childhood cancer incidence in the U.S.(1992–2004). Cancer.
112:416–432. 2008. View Article : Google Scholar
|
|
4
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kinzler KW, Nilbert MC, Su LK, Vogelstein
B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P and
McKechnie D: Identification of FAP locus genes from chromosome
5q21. Science. 253:661–665. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y,
Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P:
Mutations of chromosome 5q21 genes in FAP and colorectal cancer
patients. Science. 253:665–669. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
9
|
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa
N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al:
AXIN1 mutations in hepatocellular carcinomas, and growth
suppression in cancer cells by virus-mediated transfer of AXIN1.
Nat Genet. 24:245–250. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Korinek V, Barker N, Morin PJ, van Wichen
D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive
transcriptional activation by a beta-catenin-Tcf complex in
APC−/−colon carcinoma. Science. 275:1784–1787. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roose J, Huls G, van Beest M, Moerer P,
van der Horn K, Goldschmeding R, Logtenberg T and Clevers H:
Synergy between tumor suppressor APC and the beta-catenin-Tcf4
target Tcf1. Science. 285:1923–1926. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jho EH, Zhang T, Domon C, Joo CK, Freund
JN and Costantini F: Wnt/beta-catenin/Tcf signaling induces the
transcription of Axin2, a negative regulator of the signaling
pathway. Mol Cell Biol. 22:1172–1183. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ng TL, Gown AM, Barry TS, Cheang MC, Chan
AK, Turbin DA, Hsu FD, West RB and Nielsen TO: Nuclear beta-catenin
in mesenchymal tumors. Mod Pathol. 18:68–74. 2005. View Article : Google Scholar
|
|
19
|
Jang M, Cai L, Udeani GO, et al: Cancer
chemopreventive activity of resveratrol, a natural product derived
from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Joe AK, Liu H, Suzui M, Vural ME, Xiao D
and Weinstein IB: Resveratrol induces growth inhibition, S-phase
arrest, apoptosis, and changes in biomarker expression in several
human cancer cell lines. Clin Cancer Res. 8:893–903.
2002.PubMed/NCBI
|
|
21
|
Athar M, Back JH, Tang X, et al:
Resveratrol: A review of preclinical studies for human cancer
prevention. Toxicol Appl Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alkhalaf M and Jaffal S: Potent
antiproliferative effects of resveratrol on human osteosarcoma
SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53
cascade. Free Radic Biol Med. 41:318–325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alkhalaf M, El-Mowafy A, Renno W, Rachid
O, Ali A and Al-Attyiah R: Resveratrol-induced apoptosis in human
breast cancer cells is mediated primarily through the
caspase-3-dependent pathway. Arch Med Res. 39:162–168. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He N and Zhang Z: Baicalein suppresses the
viability of MG-63 osteosarcoma cells through inhibiting c-MYC
expression via Wnt signaling pathway. Mol Cell Biochem.
405:187–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Nakamura T, Hamada F, Ishidate T, Ishidate
T, Anai K, Kawahara K, Toyoshima K and Akiyama T: Axin, an
inhibitor of the Wnt signalling pathway, interacts with
beta-catenin, GSK-3beta and APC and reduces the beta-catenin level.
Genes Cells. 3:395–403. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-Where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar
|
|
28
|
Yamamoto N and Tsuchiya H: Chemotherapy
for osteosarcoma-where does it come from? What is it? Where is it
going? Expert Opin Pharmacother. 14:2183–2193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyaki M, Iijima T, Kimura J, Yasuno M,
Mori T, Hayashi Y, Koike M, Shitara N, Iwama T and Kuroki T:
Frequent mutation of beta-catenin and APC genes in primary
colorectal tumors from patients with hereditary nonpolyposis
colorectal cancer. Cancer Res. 59:4506–4509. 1999.PubMed/NCBI
|
|
30
|
Morin PJ: β-catenin signaling and cancer.
Bioessays. 21:1021–1030. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
32
|
Polakis P: The oncogenic activation of
beta-catenin. Curr Opin Genet Dev. 9:15–21. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He T-C, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hedberg Y, Ljungberg B, Roos G and
Landberg G: Expression of cyclin D1, D3, E and p27 in human renal
cell carcinoma analysed by tissue microarray. Br J Cancer.
88:1417–1423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang LQ, Fang DC, Wang RQ and Yang SM:
Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of
gastric cancer cells induced by tumor necrosis factor related
apoptosis inducing ligand. World J Gastroenterol. 10:22–25.
2004.
|
